Our Principal, Ms. Yolanda Wang, was invited to join a panel discussion on the first day of BIOHK this year, which took place on Wednesday, September 13, 2023 at HKCEC, on the topic of “Ethics in the Biotech Industry.”

The panel was moderated by Ms. Monin Ung of Mung Legal and included esteemed panelists Prof. Yi Rao from Capital Medical University and Prof. Dong Dong from CUHK.

During the discussion, Yolanda shared her experiences regarding the ethical challenges she encountered in her career in IP and provided insights on the concept of ethics in the biotech industry from the perspective of a patent practitioner.



Our Past Events

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

26 November 2025

Jennifer Che has been Recognized as IAM Global Leaders 2026

4 November 2025

Eagle IP is Coming to San Francisco and Washington DC!

15 October 2025

Jennifer Che has been listed on the IAM Strategy 300

15 August 2025

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

3 July 2025

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

13 June 2025

Recommended Insights

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

7 February 2024
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]
Read more >

Foreign companies transferring IP out of China: things to know

25 October 2018
Inventions made in China Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent […]
Read more >

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

10 March 2025
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]
Read more >

Breaking: China Released New Implementation Measures for the New Patent Linkage System

14 July 2021
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
Read more >
Top crossarrow-right